|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM20504042X |
| 003 |
DE-627 |
| 005 |
20231223233153.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231223s2011 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2010.12.010
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0683.xml
|
| 035 |
|
|
|a (DE-627)NLM20504042X
|
| 035 |
|
|
|a (NLM)21233022
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Dhodapkar, Madhav V
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Harnessing natural killer T (NKT) cells in human myeloma
|b progress and challenges
|
| 264 |
|
1 |
|c 2011
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 03.10.2011
|
| 500 |
|
|
|a Date Revised 20.10.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2010 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Multiple myeloma is a hematologic malignancy characterized by growth of malignant plasma cells in the bone marrow. Tumor cells in myeloma express CD1d and are sensitive to lysis by CD1d restricted natural killer T (NKT) cells. Here we discuss recent studies to harness the properties of these cells in the context of human myeloma. In spite of large body of preclinical data, attempts to fully harness the properties of these cells in the clinic are in early stages. Early phase clinical studies document the capacity of human monocyte-derived dendritic cells to expand NKT cells in vivo in myeloma patients. These results have set the stage for ongoing studies combining NKT activation with immune-modulatory drugs. Lessons learnt from these studies may inform the optimal application of human NKT based therapies in other settings as well
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
7 |
|a Adjuvants, Immunologic
|2 NLM
|
| 650 |
|
7 |
|a Antigens, CD1d
|2 NLM
|
| 650 |
|
7 |
|a Galactosylceramides
|2 NLM
|
| 650 |
|
7 |
|a KRN 7000
|2 NLM
|
| 650 |
|
7 |
|a WX671898JF
|2 NLM
|
| 700 |
1 |
|
|a Richter, Joshua
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 140(2011), 2 vom: 15. Aug., Seite 160-6
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:140
|g year:2011
|g number:2
|g day:15
|g month:08
|g pages:160-6
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2010.12.010
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 140
|j 2011
|e 2
|b 15
|c 08
|h 160-6
|